Sandoz Antitrust Resolution
Sandoz Settles Remaining US Antitrust Claims for $450 Million, Ending Generic Drug Litigation
Anonymous
Key Points
1
The antitrust litigation traces back to 2020, involving a separate criminal settlement in the US where Sandoz agreed to pay about $195 million related to conspiracy in the generic-drug market.
2
Sandoz’s US settlements include two parallel agreements: one with the lead counsel for a consortium of 43 states and territories, and another with indirect reseller plaintiffs, each requiring approvals from the respective authorities.
3
The lead-counsel arrangement for the 43-state consortium signals a centralized, negotiated approach to resolving the remaining government claims in the US generic-drug pricing matter.
4
To reflect the settlements, Sandoz has increased its previously recorded litigation provision, indicating an accounting adjustment tied to the expected settlement costs.
5
The package of settlements follows earlier deals with federal authorities and other plaintiff classes, as part of Sandoz’s broader push to close legacy US litigation in the generic-drug antitrust saga.
Sandoz has agreed to pay roughly $478.5 million to settle the bulk of its remaining US antitrust claims over generic drug price-fixing, according to Fierce Pharma and France 24. The Swiss drugmaker and its subsidiary, Fougera Pharmaceuticals, will pay $400 million to a consortium of 43 US states and territories over seven years, starting in 2027, plus about $50 million to states that settled earlier.
A separate $28.5 million deal resolves class action claims from indirect resellers, France 24 reported. Together, the agreements would close all remaining federal and state government claims tied to the generic-drug pricing scandal. Sandoz said it is not admitting wrongdoing and that the deals will not affect its 2026 financial guidance.
How a Decade-Long Price-Fixing Scandal Reached This Point
The antitrust saga began to unfold around 2020, when Sandoz reached a criminal settlement with US authorities worth roughly $195 million. That deal covered Sandoz's role in an alleged conspiracy to fix prices in the generic-drug market. Generic drugs are cheaper copies of brand-name medicines, and the US market for them is enormous — making the alleged price-fixing a major concern for consumers, states, and insurers.
Civil lawsuits from states and private buyers followed the criminal case. France 24 reported that Sandoz and Fougera Pharmaceuticals have now reached deals to put those civil claims to rest. The settlements still need approval from courts and relevant state authorities before they take effect.
Two Parallel Deals Cover Government and Private Claims
The larger agreement covers a consortium led by attorneys general from 43 US states and territories. Sandoz will pay $400 million in installments over seven years, with payments beginning in 2027. An additional roughly $50 million goes to states that had already settled separately, France 24 reported.
The second deal targets indirect resellers — businesses that bought generic drugs through a middleman rather than directly from Sandoz. That class action settlement is worth $28.5 million, according to 24 News HD. Both agreements are subject to court approval, and neither requires Sandoz to admit any wrongdoing.
Sandoz Books Larger Provision but Shields Its Outlook
To cover the settlement costs, Sandoz increased its litigation provision — money set aside on its balance sheet to pay future legal bills. The company did not specify the exact new provision amount, but said the adjustment reflects the expected cost of both deals. A provision increase typically signals that a company is confident a deal will close.
Sandoz told investors the settlements will not change its 2026 financial guidance or its medium-term outlook, according to Fierce Pharma. That signals the company had already planned for these costs. With payments not starting until 2027, the near-term cash impact is limited.
Sandoz Moves to Close the Book on US Antitrust Legacy
These settlements are part of a broader push by Sandoz to clear its US legal backlog. The company has now resolved claims with federal authorities, multiple plaintiff classes, and a large coalition of state governments. Fierce Pharma compared the strategy to that of Johnson & Johnson, which used staged settlements to put mass litigation behind it.
If courts and states approve the deals, Sandoz will have put roughly $673.5 million total toward US antitrust liability — counting the earlier $195 million criminal settlement. That is a steep price, but analysts say it removes a significant cloud of uncertainty for the company as it focuses on growing its generics business independently from Novartis.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
15
Articles
80
Reach
95
A
AnonymousAuthor
